Concepedia

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients

Sook Jin Seong, Minkyung Lim, Sang Kyun Sohn, James Moon, Subi Oh, B.-S. Kim, Hun-Mo Ryoo, Joo-Seop Chung, Yoosun Joo, Soo‐Mee Bang,

Annals of Oncology · 2012 · 79 citations · 20 references

DOIFull text

Open access

Concepts

References

20

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

Timothy P. Hughes, Jaspal Kaeda, Susan Branford et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text

, , +13

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Richard A. Larson, Brian Druker, François Guilhot et al. · Blood · 2008 · 637 citations · Full text

, , +6

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stéphane Picard, Karine Titier, Gabriel Étienne et al. · Blood · 2006 · 604 citations · Full text

, , +13

Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients

Bin Peng, Michael Hayes, Debra Resta et al. · Journal of Clinical Oncology · 2004 · 470 citations · Full text

, , +13

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

Herman Burger, Hans van Tol, Antonius W.M. Boersma et al. · Blood · 2004 · 415 citations · Full text

, , +11